ACADIA PHARMACEUTICALS INC. Intangible Assets, Net (Excluding Goodwill)
ACADIA PHARMACEUTICALS INC. (ACAD) had Intangible Assets, Net (Excluding Goodwill) of $0 as of 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2022-03-01
- 2021-12-31: Intangible Assets, Net (Excluding Goodwill) $0.00.
- 2021-06-30: Intangible Assets, Net (Excluding Goodwill) $369.00K.
- 2021-03-31: Intangible Assets, Net (Excluding Goodwill) $738.00K.
- 2020-12-31: Intangible Assets, Net (Excluding Goodwill) $1.11M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2021-06-30 | $369.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $738.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.11M 10-K · filed 2022-03-01 |
| 2020-09-30 | $1.48M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $1.85M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.21M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $2.58M 10-K · filed 2021-02-25 |
| 2019-09-30 | $2.95M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $3.32M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $3.69M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $4.06M 10-K · filed 2020-02-27 |
| 2018-09-30 | $4.43M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $4.80M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $5.17M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $5.54M 10-K · filed 2019-02-27 |
| 2017-09-30 | $5.91M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $6.28M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $6.65M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $7.01M 10-K · filed 2018-02-27 |
| 2016-09-30 | $7.38M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $7.75M 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |